PSY14 Pharmacoeconomic Evaluation of Intravenous Ferric Carboxymaltose and Iron Sucrose in Correction of Preoperative Anaemia in Patients Undergoing Major Elective Surgery  by Gorokhova, S.G. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A379
Objectives: The purpose of the budget impact analysis (BIA) was to estimate 
financial consequences of deferasirox (DSX) reimbursement within the health care 
treatment programme (HTP) on the budget of the National Health Fund (NHF) in 
Poland. MethOds: BIA was performed for a 2-year time horizon (July 2012 - June 
2014) from the Polish public payer perspective. The target population qualified to the 
HTP programme were children and adolescents (age ≤ 18 years) with iron overload 
due to frequent blood transfusions. The population was estimated on the basis of 
medical expert opinion. Two scenarios were compared: the “existing scenario” – 
without reimbursement of DSX (only standard of care with deferoxamine (DFO) 
was available) and the “new scenario” – DSX reimbursed as part of HTP. In the 
analysis, only direct medical costs were included: costs of drugs and their admin-
istration, costs of monitoring and costs of blood transfusions. It was assumed that 
the cost of deferoxamine was included in the cost of hospitalization procedures 
related to chelation therapy. Due to the lack of available data on adverse events 
(AE) incidence during therapy with deferasirox or deferoxamine, the costs of AE’s 
treatment were not considered. The calculations were performed in Microsoft Office 
Excel. Results: NHF annual expenditures related to the introduction of deferasirox 
reimbursement will increase by PLN 454 thousand in the first year and by PLN 
434 thousand in the second year of reimbursement compared with the “existing 
scenario.” cOnclusiOns: The positive reimbursement decision for DSX enables 
patients with iron overload access to safe and effective therapy. Deferasirox therapy 
will allow young patients to go back to normal functioning in their families and in 
society. The positive reimbursement decision will also contribute to improving the 
quality of life, self-esteem and emotional state of the patients.
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Pharmacoeconomic StudY of nutrition SuPPort (nS) uSage during 
intenSive treatment
Metelkin I., Yagudina R., Kulikov A.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To undertake a comparative analysis of 2 methodologies of inten-
sive treatment (IT) , precisely: IT without NS and IT taking into account NS han-
dling. MethOds: Pharmacoeconomic analysis “budget impact” was provided. Only 
direct costs were taken into account: expenses for drug therapy, hospitalization 
(intensive care unit and medical division) and late complications (pneumonia, sepsis, 
catheter and wound infection) treatment. Effectiveness data was taken from Russian 
clinical trial: Popov T.S., Shestopalov A.E., Tsvetkov D.S., Nechaev D.S., Kuz’min M.A. 
Nutrition Day in intensive care units of the Russian Federation. National association 
of parenteral and enteral nutrition – Moscow (Russia), 2011. Four types of NS were 
compared: IT without NS; IT + enteral nutrition (EN); IT + parenteral nutrition (PN) 
and IT + combined nutrition (CN). Results: When carrying out comparative phar-
macoeconomic study all calculations were made for 3 groups of patients depending 
on their health condition: lightly-severe, moderately severe and severe. According to 
the results of calculations transfer of patients from IT without NS to IT carrying out 
NS leads to reduction of total expenses, therefore economy of money for the state. 
Independent from patient health condition – the greatest economy of money arises 
when EN is used during IT. Further on degree of expressiveness of positive economic 
effect there is PN and the least NS economic type is CN. cOnclusiOns: The results 
received during the study were analyzed and the rating of NS types, which were taking 
part in the research, from the point of view of their clinical efficiency and economic 
effectiveness for the state budget, was made.
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Objectives: To demonstrate the economic impact of using NovoSeven compared to 
Feiba for the initial treatment of mild to moderate bleeding episodes in patients with 
haemophilia A with inhibitors. MethOds: A budget impact model was developed 
based on a previous economic evaluation to calculate the annual budget impact 
and the treatment cost per episode according to the different treatment strategies. 
The model presents the costs of the strategies to treat a mild to moderate bleeding 
episode with up to three lines of treatment, in which the impact parameters are the 
weight of the patient, the dose, the efficacy and the costs of medication and admin-
istration. Three treatment strategies were used: strategy 1: NovoSeven - NovoSeven 
- NovoSeven, strategy 2: Feiba - NovoSeven - NovoSeven and strategy 3: Feiba - Feiba - 
NovoSeven. Costs per episode and annual costs were calculated based on local input 
data on costs and resources and the perspective used was of the Spanish National 
Health Service (NHS). Results: Total costs per patient for one bleeding episode 
were € 10,253, € 11,852 and € 12,042 for strategies 1, 2 and 3, respectively. Lower total 
costs per patient with NovoSeven are due to a reduced need for further treatment 
and associated hospitalisation. Only using NovoSeven saves € 23,985 compared to 
strategy 2 and € 26,842 compared to strategy 3 annually. cOnclusiOns: The use 
of NovoSeven in all three lines of treatment in patients with in haemophilia A 
compared to using Feiba in the first line of treatment and in the first and second 
line of treatment saves € 1,599 and € 1,789 respectively per bleeding episode. This is 
mainly due to reduced need for further treatment and associated hospitalisation 
with NovoSeven. Annual cost savings using only NovoSeven are the consequence 
of lower drug cost and higher treatment efficacy with NovoSeven.
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Avoidance of administration costs for infused treatments could offset the higher 
acquisition cost for deferasirox. Additional data is required to confirm efficacy of 
other treatments in patients with NTDT.
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the Budget imPact of Qutenza® for the treatment of neuroPathic 
Pain in Sweden
Chambers C.1, Nordling S.2, Smith D.3, Bentley A.3
1Astellas, Chertsey, UK, 2Astellas Pharma, Kastrup, Denmark, 3Abacus International, Bicester, UK
Objectives: Neuropathic pain (NP) is a common disorder which can be chronic, 
severe, and disabling and is associated with reductions in quality of life and consid-
erable costs. Current first-line treatments for NP include tricyclic antidepressants 
and anti-convulsants. QUTENZA® is a cutaneous patch that allows rapid dermal 
delivery of capsaicin directly to the source of pain. The objective of this analysis 
is to estimate the burden of NP, current treatment costs and the budget impact of 
introducing QUTENZA® for the treatment of peripheral NP in non-diabetic adults 
in Sweden. MethOds: We constructed a budget impact calculator to estimate the 
impact of introducing QUTENZA® for 100 people in Sweden. Drug costs for each 
management strategy are annual costs, based on estimated market shares, and 
range from SEK 231 to SEK 5,806 (with SEK 3,909 for QUTENZA®). We assumed a 50% 
uptake of QUTENZA® and a 50% reduction in the use of concomitant medication in 
the model, based on evidence from real-world data. Results: For a NP population 
of n= 100, the cost of current prescribing was estimated at SEK 1.00 million. The cost 
of alternative prescribing including QUTENZA® was estimated at SEK 1.01 million. 
The annual cost of treating a patient with QUTENZA® was estimated as SEK 11,941. 
The estimated cumulative budget impact by year (for 100 patients, with the market 
share rising from 10% in Year 1 to 100% in Year 5) ranged from SEK 9,664 in Year 1 to 
SEK 67,949 in Year 5. cOnclusiOns: The introduction of QUTENZA® results in a 
budget impact of SEK 67,949 for 100 patients over 5 years. This represents a minimal 
additional expenditure and could be considered good value for money given the 
added benefits for patients with NP in Sweden.
PSY9
Pharmacoeconomic analYSiS of anti-inhiBitor coagulant comPlex 
(aicc) in the treatment of inhiBitor hemoPhilia
Yagudina R., Kulikov A., Zinchuk I., Molchanova N.
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Objectives: To identify the dominant scheme of inhibitor hemophilia bypassing 
agents therapy (comparing three regimens: Eptacog alfa monotherapy, combination 
therapy «Eptacog alfa + AICC» and «AICC + Eptacog alfa»). MethOds: Based on 
the crossover clinical research FENOC (Jan Astermark, Sharyne M., Donfield, 2007) 
the annual cost of treatment by bypassing agents in mild, moderate, severe and 
life-threatening bleeding is estimated. The analysis of the direct and indirect costs 
is conducted. Direct costs include the cost of bypassing agents therapy, the cost of 
emergency medical care, the cost of inpatient and outpatient treatment. Indirect 
costs include cost of patient’s disability, GDP losses caused by mortality and dis-
ability, and sick-pay. Value of bypassing agents on demand therapy in three dosing 
schemes is identified: monotherapy Eptacog alfa (there is no alternative treatment), 
«Eptacog alfa + AICC» (after the first episode of bleeding no response patients to 
treatment from Eptacog alfa to AICC transferred) and «AICC + Eptacog alfa» (after 
the first episode of bleeding no response patients to treatment from AICC to Eptacog 
alfa transferred). Results: Based on the clinical study FENOC, indicated that there 
is no significant difference in efficacy AICC and Eptacog alfa therapy in patients 
susceptible to this treatment. An analysis of the direct and indirect costs shows that 
the costs of the annual course of treatment of 142 patients in Russia are 66 mil EUR, 
60,7 mil EUR and 53,1 mil EUR for treatments Eptacog alfa monotherapy, «Eptacog 
alfa + AICC» and «AICC + Eptacog alfa» schemes respectively. cOnclusiOns: It is 
determined that the regimen «AICC + Eptacog alfa», will reduce reduces costs rela-
tive to the current treatment regimen for 12,9 mil EUR (19,54%) or provide addition-
ally treat of 34 patients of this disease.
PSY10
Potential financial imPact of Sugammadex in anaeSthetic 
dePartmentS: a Budget imPact analYSiS on PotentiallY Short 
ProcedureS reQuiring neuromuScolar Blockade
Povero M., Pradelli L.
AdRes HE&OR, Turin, Italy
Objectives: To evaluate the economic impact on Italian NHS of using sugam-
madex within anaesthetic departments instead of neostigmine. MethOds: The 
number of procedures using neuromuscular blockings agents (NMBA) potentially 
eligible for sugammadex was elaborated by hospital discharge data available in 
Italy for the year 2010. Reduction in postoperative residual curarisation (PORC) 
rate and saved time allocated to extra procedures were taken from two recent 
meta-analyses. Costs considered in the analysis were drugs acquisition costs 
(sugammadex and neostigmine) and PORC management costs. Results: Overall 
annual costs of sugammadex and neostigmine usage result about 34.5 and 31.6 
Million Euro, respectively. Sugammadex prevents 99% of PORC episodes on 428,995 
procedures; this is associated with savings of more than 30 Million Euro. Also the 
saved time in surgery procedures due to sugammadex results in an annual savings 
of 154,867 (36.1%) hours that could be used for further procedures. cOnclusiOns: 
Sugammadex radically reduces PORC episodes during post-operative and it allows 
for shorter operating room occupation.
PSY11
the Budget imPact analYSiS of deferaSirox for the treatment of 
iron overload due to freQuent Blood tranSfuSionS in children and 
adoleScentS (age ≤ 18 YearS)
Walczak J.1, Obrzut G.1, Sołtys E.1, Laczewski T.2
1Arcana Institute, Cracow, Poland, 2Novartis Poland Sp. z o.o., Warsaw, Poland
A380  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
for sensitivity analyses showed cost-savings ranging from € 22,525 to € 996,384 of 
prophylaxis with aPCC vs. on-demand with rFVIIa. cOnclusiOns: Three times/
week aPCC prophylaxis could reduce 16% the total treatment cost of severe HA 
with inhibitor, saving up to € 98,000/patient/year.
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relationShiP Between BodY maSS index and health care coStS BY 
Place of Service in emPloYed adultS
Abouzaid S.1, Kleinman N.L.2, Andersen L.2, Wang Z.1, Powers A.1
1Eisai Inc., Woodcliff Lake, NJ, USA, 2HCMS Group, Cheyenne, WY, USA
Objectives: While previous studies have shown that overweight and obesity are 
associated with higher costs, less is known about health care costs by place of 
service (POS) at various levels of BMI. This study measures the impact of BMI as a 
continuous variable on health care cost at different places of service. POS categories 
include: pharmacy, doctor’s office, inpatient hospital, outpatient hospital or clinic, 
emergency department, laboratory, and other. MethOds: Using 2003-2012 retro-
spective data from large employers throughout the United States, employees’ BMI 
values were calculated using health risk appraisal data. All study employees were 
> = 18, had > = 12 months of health plan coverage after their index BMI screening 
date, and had no medical claims indicating pregnancy. Employees with BMI< 18 (1st 
percentile) or BMI> 47 (99thpercentile) were excluded. Generalized additive models 
on 12-month post-index POS costs produced estimates of the nonlinear relation-
ship between BMI and cost after controlling for age, gender, marital status, race, 
salary, zip-code region and index year. Results: This study included 71,633 eligible 
employees; 32.0% were female. The average BMI, age and annual salary were 27.3, 
39.8 years and $81,382, respectively. Costs increased significantly with BMI in each 
POS (P< 0.001). Total adjusted annual per-employee health care cost estimates at BMI 
values of 25, 30, 35, and 45 were $3043, $3932, $4357, and $7248, respectively. Cost 
estimates by POS at these BMI values were: Pharmacy ($706, $903, $1106, $1372), 
Inpatient ($398, $678, $643, $2440), Outpatient ($799, $1057, $1113, $1516), Office 
($939, $1044, $1174, $1495), Emergency ($131, $159, $200, $186), Laboratory ($34, $38, 
$46, $43), and Other ($35, $53, $74, $196), respectively. cOnclusiOns: Employees 
with higher BMI levels incurred more cost at each of the 7 places of service. Because 
of the high prevalence of overweight and obesity, these costs represent a significant 
burden for US employers.
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cohort analYSiS aSSeSSing health care coStS aSSociated with 
oBeSitY at variouS PlaceS of Service in emPloYed adultS
Abouzaid S.1, Kleinman N.L.2, Andersen L.2, Wang Z.1, Powers A.1
1Eisai Inc., Woodcliff Lake, NJ, USA, 2HCMS Group, Cheyenne, WY, USA
Objectives: This study determines the distribution of health care costs by place 
of service (POS; pharmacy, doctor’s office, inpatient hospital, outpatient hospital 
or clinic, emergency department, laboratory, and other) among employees based 
upon body mass index (BMI). MethOds: Using 2003-2012 retrospective data from 
large employers throughout the US, employees’ BMIs from health risk appraisal data 
defined three main cohorts (BMI< 27 [normal weight], 27< = BMI< 30 [overweight] and 
BMI> = 30 [obese]). The 27< = BMI< 30 cohort was further divided into 3 comorbidity 
subcohorts: those without diabetes, hypertension or dyslipidemia (NonT2DHtnDys), 
those with hypertension or dyslipidemia without diabetes (HtnDys), and those with 
diabetes with or without hypertension or dyslipidemia (T2D). All eligible employees 
were aged> = 18, had > = 12 months post-index health plan coverage, and had no 
pregnancy claims. Annual post-index costs were compared between cohorts and 
between subcohorts using two-part regression modeling, controlling for age, gender, 
marital status, race, salary, region, and index year. Results: This study included 
39,696 (BMI< 27), 14,281 (27< = BMI< 30), and 18,801 (BMI> = 30) eligible employees, 
with total adjusted health care costs of $3,191, $3,695, and $4,844, respectively. 
Employees with higher BMI were significantly more likely to incur health care costs 
in every POS category. Obese employees (BMI> = 30) had particularly high inpatient 
costs compared to other cohorts, averaging twice the cost of the BMI< 27 cohort 
($919 vs. $431, P< 0.05). Total costs among subcohorts of 27< = BMI< 30 were $2,863 
(NonT2DHtnDys), $5,271 (HtnDys), and $7,594 (T2D). NonT2DHynDys employees had 
significantly lower health care cost than other subcohorts in every POS category. 
The T2D subcohort had significantly higher pharmacy, inpatient, doctor’s office, 
laboratory and other health care costs when compared to HtnDys. cOnclusiOns: 
Employees with higher BMI incurred higher average health care costs than other 
employees at all places of service. Comorbidities, particularly diabetes, exacerbate 
health care costs of overweight employees. This represents a significant economic 
burden for US employers given the high prevalence of overweight and obesity.
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haemoPhilia a: annual coSt comPariSon Between fl-rfviii and Bdd-
rfviii in france: we Should comPare the coSt Per Patient inStead of 
the Price Per unit
Haarmann H.1, Epstein J.2, Grumel O.3
1Baxter Healthcare, Opfikon, Switzerland, 2Baxter BioScience, Westlake Village, CA, USA, 3Baxter 
France, Maurepas, France
Objectives: Hemophilia A is rare bleeding disorder where patients have defective 
or deficient levels of coagulation factor VIII (FVIII). Recombinant FVIIII (rFVIII) are 
manufactured to treat the patients, either as a full-length rFVIII (FL-rFVIII) mol-
ecule replicating natural human FVIII or with the B-domain deleted (BDD-rFVIII). It 
has been suggested that Deletion of B domain had been implemented to improve 
production profitability. However, this deletion has been shown to induce increase 
factor consumption by 32.8% in the US (Epstein 2011) and also may increase the 
risk of developing inhibitors for previously treated patients (PTP) Hazard Ratio= 10.8 
(Aledort 2011). Both differences can have an important impact on patient health 
and on the national health care budget. MethOds: A Excel-based decision tree 
model had been developed to compare the overall cost to treat severe haemophilia 
A patients from a health care system perspective with the most used FL-rFVIII and 
Objectives: To assess the cost-effectiveness of ferric carboxymaltose (FCM) and 
iron sucrose (IS) in the correction of iron-deficiency anaemia (IDA) before elec-
tive major surgery in non-cardiac surgical patients and predict potential budget 
expenses for the day care services and blood transfusions. MethOds: The pharma-
coeconomic model was developed based on the data from multicentre prospective 
study (E. Bisbe et al., 2011) on the efficacy of FCM and IS for correcting preopera-
tive anaemia in patients undergoing major elective non-cardiac surgery. The cost-
effectiveness of two intravenous iron formulations was measured as total costs of 
medicines and day care services per one patient attained iron replenishment or per 
one patient without IDA at the end of treatment. Budget impact analysis included 
expenses for the day care services and blood transfusion procedures during intraop-
erative and/or postoperative period. Sensitivity analysis was performed by including 
in the model of iron sucrose similars (ISSs). It was considered that treatment with 
ISSs requires dose increase up to 120-135% of dose of the original IS (E. Lee et al., 
2013; J. Rottermbourg et al., 2010). Results: The clinical efficacy of FCM was higher 
compared to that of IS, this was also reflected in better pharmacoeconomic profile 
of FCM. The CERs were 14,473.61 RUB and 15,222.83 RUB per one patient attained 
iron replenishment in the FCM and IS groups, respectively. Treatment with FCM was 
associated with 2.5-fold lower costs of day care services and 2.7-fold lower expenses 
for blood transfusion procedures. Additional expenses for the day care services were 
required for patients received ISSs due to increased frequency of injections; this was 
resulted in the highest CERs in the ISS group. cOnclusiOns: The present study 
has demonstrated that administration of FCM is economically effective strategy to 
replenish body iron stores and correct IDA in surgical patients.
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coSt analYSiS of a fiBrin Sealant Patch for mild, moderate and 
ProBlematic Soft tiSSue Surgical Bleeding: a hoSPital PerSPective
Corral M.1, Ferko N.2, Hollmann S.2, Delatore P.3, Jamous N.4, Brown S.T.2, Rubinger D.2
1Ethicon Biosurgery, Somerville, NJ, USA, 2Cornerstone Research Group, Burlington, ON, Canada, 
3Ethicon, Inc, Somerville, NJ, USA, 4Ethicon Biosurgery, Norderstedt, Germany
Objectives: Although there are several hemostats available, drawbacks include 
limitations with efficacy on first attempt and sub-optimal ease-of-use. Literature 
suggests that more efficacious hemostats may avert hospital resources and offset 
upfront acquisition costs. A study was conducted to estimate the cost impact of a 
novel fibrin sealant patch (i.e., EVARREST™) versus standard of care (SoC) in mild-
moderate and problematic soft tissue surgical bleeding. MethOds: An economic 
model was developed to quantify 30-day cost impact of EVARREST from a U.S. hospi-
tal perspective. Key resources, collected from two trials, included quantity of initial 
treatment and re-treatment, operating time, hospitalization, transfusion risk, amount 
transfused, and ventilator utilization. SoC was composed of Surgicel (mild-moderate 
bleeding) or Surgicel (88%) and conventional methods (12%) (problematic bleeding). 
The primary analysis included resources clinically related to the significant hemo-
stasis benefit of EVARREST vs. control (i.e., initial and re-treatment, operating time 
and transfusion). A secondary analysis included all resources collected. Published 
data on U.S. costs were applied to resource use. Results: In problematic bleeding, 
the primary analysis predicted that EVARREST is cost-savings for the hospital vs. 
SoC (-$462 USD per patient) with robust one-way sensitivity results (range: -$199 
to -$6,212 USD). In mild-moderate bleeding, EVARREST acquisition cost is partially 
offset with a cost impact of $507 USD per patient (sensitivity range: $175 to $851 USD). 
Secondary analyses predicted further resource reduction with EVARREST leading 
to cost-savings (-$5,096 USD per patient) or reduction in cost impact ($233 USD per 
patient) for problematic and mild-moderate bleeding respectively. cOnclusiOns: 
This analysis suggests that the hospital cost impact of EVARREST depends on type 
of bleed. In problematic soft tissue bleeding, EVARREST may result in important cost 
savings for hospitals, in addition to meeting an important unmet need. Further study 
in additional populations may be required to confirm findings.
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Objectives: To estimate the treatment cost of prophylaxis and acute break-
through bleeds with Activated Prothrombin Complex Concentrate (aPCC) versus 
on-demand therapy with recombinant Factor VIIa (rFVIIa) for severe hemophilia 
A (HA) with inhibitor patients, from the Spanish Healthcare System perspec-
tive. MethOds: A cost-analysis model was used to compare annual cost per 
patient of aPCC prophylaxis versus rFVIIa on-demand treatment. Cost estimation 
included prophylaxis pharmaceutical costs (aPCC), on-demand pharmaceutical 
treatment for bleedings, bleeding events management (excluding factor), surgeries 
and HA management. Prophylaxis regimen was 75.72IU/kg three times per week. 
Total dosage for each hemorrhagic event was 673.46µg/kg for rFVIIa and 233.13U/
kg for aPCC, annual number of bleedings was 25 for on-demand therapy and 8 
for prophylaxis, assuming 69% reduction due to prophylaxis. A baseline bleed-
ing management cost (€ 2,971) was estimated based on resource use provided 
by an expert panel for four bleeding sites (joints [62.5%], muscle and soft tissue 
[28.6%], mucous membranes [3.6%] and other sites [5.4%]). Drug (ex-factory price 
with mandatory 7.5% rebate) and unitary costs (€ , 2013) were obtained from local 
databases. Results: Estimated annual treatment cost of prophylaxis with aPCC 
(€ 523,473) was lower than on-demand treatment with rFVIIa (€ 622,183). Based 
on the total agent consumption (789,109IU [aPCC] and 1,050,067µg [rFVIIa]) the 
pharmaceutical cost accounted for € 496,350 for aPCC (14.6% on-demand bleed-
ings and 85.4% prophylaxis) compared to € 543,866 for rFVIIa (average bleeding 
cost of € 9,062 [aPCC] and € 21,556 [rFVIIa]). Yearly bleedings cost was € 23,770 for 
aPCC versus € 74,963 for rFVIIa. A baseline cost for HA management (€ 2,645) and 
an average cost of surgeries (€ 708/year) were estimated for both strategies. Results 
